methoxasol 20/100 mg/ml roztok pro podání v pitné vodě
eurovet animal health, b.v. - sulfamethoxazol a trimethoprime - roztok pro podání v pitné vodě - kombinace sulfonamidů a trimethoprimu, včetně. deriváty - prasata, brojleři kura domácího
meditek trisulfa 200/40 mg/g premix pro medikaci krmiva
tekro spol. s r.o. - sulfamethoxazol a trimethoprime - premix pro medikaci krmiva - kombinace sulfonamidů a trimethoprimu, včetně. deriváty - prasata
meditek trisulfa 200/40 mg/g perorální prášek
tekro spol. s r.o. - sulfamethoxazol a trimethoprime - perorální prášek - kombinace sulfonamidů a trimethoprimu, včetně. deriváty - prasata
alfatrim alfasan 40/200 mg/ml injekční roztok
alfasan international, b.v. - sulfamethoxazol a trimethoprime - injekční roztok - kombinace sulfonamidů a trimethoprimu, včetně. deriváty - telata, psi, kočky
metaxol 20/100 mg/ml perorální roztok
eurovet animal health, b.v. - sulfamethoxazol a trimethoprime - perorální roztok - kombinace sulfonamidů a trimethoprimu, včetně. deriváty - prasata ve výkrmu, brojleři kura domácího
sumetrolim 400mg/80mg tableta
egis pharmaceuticals plc, budapešť array - 1395 sulfamethoxazol; 1490 trimethoprim - tableta - 400mg/80mg - sulfamethoxazol a trimethoprim
sumetrolim 40mg/ml+8mg/ml sirup
egis pharmaceuticals plc, budapešť array - 1395 sulfamethoxazol; 1490 trimethoprim - sirup - 40mg/ml+8mg/ml - sulfamethoxazol a trimethoprim
qaialdo
nova laboratories ireland limited - spironolakton - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 a 5.
jayempi
nova laboratories ireland limited - azathioprine - odmítnutí štěpu - imunosupresiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
kerendia
bayer ag - finerenone - renal insufficiency, chronic; diabetes mellitus, type 2 - agens působící na systém renin-angiotenzin - kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.